Versant Venture Management, LLC Akero Therapeutics, Inc. Transaction History

Versant Venture Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$8.0 - $15.01 $4.94 Million - $9.27 Million	-617,727 Closed	0 $0
Q1 2021 May 07, 2021	SELL	$24.04 - $34.19 $3.85 Million - $5.47 Million	-160,000 Reduced 20.57%	617,727 $17.9 Million
Q3 2020 Nov 12, 2020	SELL	$30.79 - $39.92 $41.2 Million - $53.4 Million	-1,337,727 Reduced 63.24%	777,727 $23.9 Million
Q2 2020 Jul 20, 2020	SELL	$19.25 - $26.76 $12 Million - $16.6 Million	-621,118 Reduced 22.7%	2,115,454 $52.7 Billion
Q1 2020 Apr 28, 2020	BUY	$12.8 - $27.05 $35 Million - $74 Million	2,736,572 New	2,736,572 $58 Billion

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.36B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Versant Venture Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Versant Venture Management, LLC with notifications on news.